VTGN: Vistagen Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for VTGN
Across the 26 sessions after earlier VTGN headlines, the stock closed higher 11 times and lower 14 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VTGN | SPY |
|---|---|---|---|
| Oct 20, 2026 | Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs | -2.6% | +0.3% |
| Sep 24, 2026 | Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder | -19.9% | -0.1% |
| Sep 22, 2026 | Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder | +7.9% | -0.0% |
| Sep 10, 2026 | Vistagen to Present at Psych Congress 2026 | +1.5% | -0.6% |
| Aug 14, 2026 | Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update | +0.5% | -0.2% |
| Aug 6, 2026 | Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder | -4.4% | -0.2% |
Quantisnow market dataNASDAQ
VTGN
Vistagen Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for VTGN
Full VTGN profile on Quantisnow Follow VTGN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time